Investing in CytomX Therapeutics, Inc. (CTMX)  ➔  Intrinsic value

Prev. close$7.91 
ModelValueUpside
Chepakovich$3.01-62%
Graham-Dodd$0.00-100%
Graham$0.00-100%
Previous Close$7.91  
Valuation MethodValuePotential 
Chepakovich Model$3.01-62%recalculate
Graham-Dodd$0.00-100%recalculate
Graham Formula$0.00-100%recalculate

Latest news

8 May

CytomX Therapeutics, Inc. (CTMX) Q1 2021 Earnings Call Transcript => Motley Fool 1:30PM

6 May

CytomX Therapeutics (CTMX) Reports Q1 Loss, Misses Revenue Estimates => Zacks 6:05PM

CytomX Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update => GlobeNewswire 4:15PM

CytomX Therapeutics, Inc. to Host Earnings Call => ACCESSWIRE 3:15PM

29 Apr

CytomX Therapeutics to Announce First Quarter 2021 Financial Results on May 6, 2021 => GlobeNewswire 8:00AM

14 Apr

CytomX Therapeutics Announces New Employment Inducement Grants => GlobeNewswire 4:01PM

JPMorgan: 2 Stocks for Stellar Long-Term Gains => TipRanks 11:42AM

24 Mar

CytomX Therapeutics to Host Virtual Investor Event on April 7, 2021 => GlobeNewswire 8:00AM

2 Mar

CytomX Therapeutics (CTMX) Upgraded to Buy: What Does It Mean for the Stock? => Zacks 12:00PM

Moving Average Crossover Alert: CytomX Therapeutics (CTMX) => Zacks 5:58AM

25 Feb

CytomX Therapeutics, Inc. (CTMX) Q4 2020 Earnings Call Transcript => Motley Fool 9:01AM

24 Feb

CytomX Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update => GlobeNewswire 4:15PM

23 Feb

A Preview Of CytomX Therapeutics's Earnings => Benzinga 10:25AM

22 Feb

CytomX Therapeutics to Present at Upcoming March Virtual Investor Conferences => GlobeNewswire 8:00AM

CytomX Therapeutics to Present at Upcoming March Virtual Investor Conferences => GlobeNewswire 8:00AM

20 Feb

We're Not Worried About CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn => Simply Wall St. 2:44AM

19 Feb

CytomX Therapeutics Announces New Employment Inducement Grant => GlobeNewswire 8:00AM

17 Feb

CytomX Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021 => GlobeNewswire 8:00AM

4 Feb

CytomX Therapeutics to Present at Guggenheim Healthcare Talks 2021 Oncology Day => GlobeNewswire 8:00AM

3 Feb

UPDATE - CytomX Therapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares => GlobeNewswire 8:19AM

CytomX Therapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares => GlobeNewswire 8:00AM

26 Jan

CytomX Therapeutics Announces Closing of Public Offering of Common Stock => GlobeNewswire 8:00AM

20 Jan

CytomX Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock => GlobeNewswire 9:50PM

19 Jan

CytomX Therapeutics Announces Proposed Public Offering of Common Stock => GlobeNewswire 4:35PM

CytomX Therapeutics Announces New Employment Inducement Grants => GlobeNewswire 8:00AM

7 Jan

CytomX Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference => GlobeNewswire 8:00AM

24 Dec

Is CTMX A Good Stock To Buy According To Hedge Funds? => Insider Monkey 10:10AM

22 Dec

CytomX Therapeutics Appoints Dr. Mani Mohindru to Board of Directors => GlobeNewswire 4:05PM

Would Shareholders Who Purchased CytomX Therapeutics' (NASDAQ:CTMX) Stock Three Years Be Happy With The Share price Today? => Simply Wall St. 12:58AM

3 Dec

CytomX Therapeutics to Present Updates on CX-2009 at 2020 San Antonio Breast Cancer Symposium => GlobeNewswire 8:00AM

11 Nov

CytomX Therapeutics to Present at Upcoming Investor Conferences => GlobeNewswire 4:01PM

7 Nov

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Just Released Its Third-Quarter Earnings: Here's What Analysts Think => Simply Wall St. 8:40AM

6 Nov

CytomX Therapeutics, Inc. (CTMX) Q3 2020 Earnings Call Transcript => Motley Fool 3:01PM

5 Nov

CytomX Therapeutics (CTMX) Reports Q3 Loss, Tops Revenue Estimates => Zacks 8:00PM

CytomX Therapeutics, Inc. to Host Earnings Call => ACCESSWIRE 4:15PM

CytomX Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update => GlobeNewswire 4:15PM

CytomX Therapeutics Announces Treatment of First Patient in Phase 2 Expansion Study of CX-2029, an Anti-CD71 Probody Drug Conjugate => GlobeNewswire 8:00AM

29 Oct

CytomX Therapeutics (CTMX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release => Zacks 12:34PM

CytomX Therapeutics to Announce Third Quarter 2020 Financial Results => GlobeNewswire 8:00AM

9 Oct

What We Learned About CytomX Therapeutics' (NASDAQ:CTMX) CEO Compensation => Simply Wall St. 8:32AM

Company description

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug for the treatment of metastatic melanoma; CX-2029, a PDC targeting CD71 for solid tumors; and BMS-986288, an anti-CTLA-4 Probody drug for solid tumors. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.